Examine National Characteristics & Outcome Measures of GERD patients using the PPI Acid Suppression Symptom (PASS) test for response

Study identifier:D9612L00096

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD patients utilizing the PPI Acid Suppression Symptom (PASS) test for response [EncomPASS].

Medical condition

Gastroesophageal Reflux

Phase

Phase 4

Healthy volunteers

Study drug

Esomeprazole

Sex

All

Actual Enrollment

2000

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 2005

Primary Completion Date: -

Study Completion Date: 01 May 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=666&filename=CSR-D9612L00096.pdf
Download
CSR-D9612L00096.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Canada

1-905-803-4853

[email protected]

Investigators

Principal Investigator

AstraZeneca Canada Medical Director

AstraZeneca